564 related articles for article (PubMed ID: 24718514)
21. Effect evaluation of denosumab combined with curettage and bone cement reconstruction in the treatment of recurrent giant cell tumor of bone around the knee joint.
Duan DK; Zhang GC; Sun BJ; Ma TX; Zhao M
Eur Rev Med Pharmacol Sci; 2023 Jun; 27(11):5039-5052. PubMed ID: 37318478
[TBL] [Abstract][Full Text] [Related]
22. Giant Cell Tumor of Bone: An Update.
Basu Mallick A; Chawla SP
Curr Oncol Rep; 2021 Mar; 23(5):51. PubMed ID: 33754215
[TBL] [Abstract][Full Text] [Related]
23. The role of Denosumab in joint preservation for patients with giant cell tumour of bone.
Perrin DL; Visgauss JD; Wilson DA; Griffin AM; Abdul Razak AR; Ferguson PC; Wunder JS
Bone Joint J; 2021 Jan; 103-B(1):184-191. PubMed ID: 33380180
[TBL] [Abstract][Full Text] [Related]
24. Denosumab treatment of inoperable or locally advanced giant cell tumor of bone.
Borkowska A; Goryń T; Pieńkowski A; Wągrodzki M; Jagiełło-Wieczorek E; Rogala P; Szacht M; Rutkowski P
Oncol Lett; 2016 Dec; 12(6):4312-4318. PubMed ID: 28101196
[TBL] [Abstract][Full Text] [Related]
25. Giant cell tumor of the bone: aggressive case initially treated with denosumab and intralesional surgery.
von Borstel D; A Taguibao R; A Strle N; E Burns J
Skeletal Radiol; 2017 Apr; 46(4):571-578. PubMed ID: 28188337
[TBL] [Abstract][Full Text] [Related]
26. Giant cell tumor of the thoracic spine completely removed by total spondylectomy after neoadjuvant denosumab therapy.
Yonezawa N; Murakami H; Kato S; Takeuchi A; Tsuchiya H
Eur Spine J; 2017 May; 26(Suppl 1):236-242. PubMed ID: 28396950
[TBL] [Abstract][Full Text] [Related]
27. Recommencement of Denosumab for Unresectable Giant Cell Tumor of the Cervical Spine: A Case Report.
Law GW; Yeo NEM; Howe TS; Tan YZ; Tan SB; Siddiqui MMA
Spine (Phila Pa 1976); 2018 May; 43(9):E551-E556. PubMed ID: 29016442
[TBL] [Abstract][Full Text] [Related]
28. Denosumab-treated giant cell tumor of bone. Its histologic spectrum and potential diagnostic pitfalls.
Roitman PD; Jauk F; Farfalli GL; Albergo JI; Aponte-Tinao LA
Hum Pathol; 2017 May; 63():89-97. PubMed ID: 28235628
[TBL] [Abstract][Full Text] [Related]
29. Clinicopathologic and molecular features of denosumab-treated giant cell tumour of bone (GCTB): Analysis of 21 cases.
Yang L; Zhang H; Zhang X; Tang Y; Wu Z; Wang Y; Huang H; Fu X; Liu J; Hogendoorn PCW; Cheng H
Ann Diagn Pathol; 2022 Apr; 57():151882. PubMed ID: 34995868
[TBL] [Abstract][Full Text] [Related]
30. Receptor-Activator of Nuclear KappaB Ligand Expression as a New Therapeutic Target in Primary Bone Tumors.
Yamagishi T; Kawashima H; Ogose A; Ariizumi T; Sasaki T; Hatano H; Hotta T; Endo N
PLoS One; 2016; 11(5):e0154680. PubMed ID: 27163152
[TBL] [Abstract][Full Text] [Related]
31. A High-grade Sarcoma Arising in a Patient With Recurrent Benign Giant Cell Tumor of the Proximal Tibia While Receiving Treatment With Denosumab.
Aponte-Tinao LA; Piuzzi NS; Roitman P; Farfalli GL
Clin Orthop Relat Res; 2015 Sep; 473(9):3050-5. PubMed ID: 25758379
[TBL] [Abstract][Full Text] [Related]
32. Denosumab for the treatment of giant cell tumor of the bone.
Brodowicz T; Hemetsberger M; Windhager R
Future Oncol; 2015; 11(13):1881-94. PubMed ID: 26161925
[TBL] [Abstract][Full Text] [Related]
33. Neoadjuvant denosumab for extensive giant cell tumor in os ischium: a case report.
van der Heijden L; van de Sande MA; Hogendoorn PC; Gelderblom H; Dijkstra PD
Acta Orthop; 2015 Jun; 86(3):393-5. PubMed ID: 25684041
[No Abstract] [Full Text] [Related]
34. Golden bullet-denosumab: early rapid response of metastatic giant cell tumor of the bone.
Demirsoy U; Karadogan M; Selek Ö; Anik Y; Aksu G; Müezzinoglu B; Corapcioglu F
J Pediatr Hematol Oncol; 2014 Mar; 36(2):156-8. PubMed ID: 24072245
[TBL] [Abstract][Full Text] [Related]
35. Denosumab treated giant cell tumour of bone: a morphological, immunohistochemical and molecular analysis of a series.
Girolami I; Mancini I; Simoni A; Baldi GG; Simi L; Campanacci D; Beltrami G; Scoccianti G; D'Arienzo A; Capanna R; Franchi A
J Clin Pathol; 2016 Mar; 69(3):240-7. PubMed ID: 26338802
[TBL] [Abstract][Full Text] [Related]
36. Short-term Preoperative Denosumab With Surgery in Unresectable or Recurrent Giant Cell Tumor of Bone.
Zhang RZ; Ma TX; Qi DW; Zhao M; Hu T; Zhang GC
Orthop Surg; 2019 Dec; 11(6):1101-1108. PubMed ID: 31762217
[TBL] [Abstract][Full Text] [Related]
37. Malignancy in giant cell tumor of bone: analysis of an open-label phase 2 study of denosumab.
Palmerini E; Seeger LL; Gambarotti M; Righi A; Reichardt P; Bukata S; Blay JY; Dai T; Jandial D; Picci P
BMC Cancer; 2021 Jan; 21(1):89. PubMed ID: 33482769
[TBL] [Abstract][Full Text] [Related]
38. Giant cell tumours of bone treated with denosumab: histological, immunohistochemical and H3F3A mutation analyses.
Kato I; Furuya M; Matsuo K; Kawabata Y; Tanaka R; Ohashi K
Histopathology; 2018 May; 72(6):914-922. PubMed ID: 29206281
[TBL] [Abstract][Full Text] [Related]
39. Histomorphometric Analysis of Pre- and Post-Denosumab-Treated Giant Cell Tumor of Bone.
Ud Din N; Umer M; Park YK
Int J Surg Pathol; 2020 Dec; 28(8):859-867. PubMed ID: 32429739
[No Abstract] [Full Text] [Related]
40. Histone H3.3 mutation in giant cell tumor of bone: an update in pathology.
Yamamoto H; Ishihara S; Toda Y; Oda Y
Med Mol Morphol; 2020 Mar; 53(1):1-6. PubMed ID: 31748824
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
